These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 33331943

  • 1. Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach.
    Özen S, Sag E, Ben-Chetrit E, Gattorno M, Gül A, Hashkes PJ, Kone-Paut I, Lachmann HJ, Tsitsami E, Twilt M, Benedetti F, Kuemmerle-Deschner JB.
    Rheumatology (Oxford); 2021 Aug 02; 60(8):3799-3808. PubMed ID: 33331943
    [Abstract] [Full Text] [Related]

  • 2. Adherence to best practice consensus guidelines for familial Mediterranean fever: a modified Delphi study among paediatric rheumatologists in Turkey.
    Kavrul Kayaalp G, Sozeri B, Sönmez HE, Demir F, Cakan M, Oztürk K, Karadag SG, Otar Yener G, Ozdel S, Baglan E, Celikel E, Sahin N, Gezgin Yildirim D, Eker Omeroglu R, Aktay Ayaz N, PeRA-Research Group.
    Rheumatol Int; 2022 Jan 02; 42(1):87-94. PubMed ID: 33454820
    [Abstract] [Full Text] [Related]

  • 3. Treat-to-target strategies for the management of familial Mediterranean Fever in children.
    Ehlers L, Rolfes E, Lieber M, Müller D, Lainka E, Gohar F, Klaus G, Girschick H, Hörstermann J, Kümmerle-Deschner J, Brunner J, Palm-Beden K, Tenbrock K, von Wrangel L, Faßhauer M, Blank N, Trauzeddel R, von Stuckrad ASL, Higgins S, Welzel T, Lutz T, Hentgen V, Foell D, Wittkowski H, Kallinich T.
    Pediatr Rheumatol Online J; 2023 Sep 26; 21(1):108. PubMed ID: 37752496
    [Abstract] [Full Text] [Related]

  • 4. EULAR recommendations for the management of familial Mediterranean fever.
    Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, Ozdogan H, Abu I, Gattorno M, Hawkins PN, Yuce S, Kallinich T, Bilginer Y, Kastner D, Carmona L.
    Ann Rheum Dis; 2016 Apr 26; 75(4):644-51. PubMed ID: 26802180
    [Abstract] [Full Text] [Related]

  • 5. Update on the management of colchicine resistant Familial Mediterranean Fever (FMF).
    El Hasbani G, Jawad A, Uthman I.
    Orphanet J Rare Dis; 2019 Oct 15; 14(1):224. PubMed ID: 31615541
    [Abstract] [Full Text] [Related]

  • 6. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
    Kurt T, Aydın F, Nilüfer Tekgöz P, Sezer M, Uncu N, Çelikel Acar B.
    Int J Rheum Dis; 2020 Jul 15; 23(7):977-981. PubMed ID: 32558310
    [Abstract] [Full Text] [Related]

  • 7. The Value of Serum Amyloid A Levels in Familial Mediterranean Fever to Identify Occult Inflammation During Asymptomatic Periods.
    Çakan M, Karadağ ŞG, Tanatar A, Sönmez HE, Ayaz NA.
    J Clin Rheumatol; 2021 Jan 01; 27(1):1-4. PubMed ID: 31524848
    [Abstract] [Full Text] [Related]

  • 8. Diagnostic validity of colchicine in patients with Familial Mediterranean fever.
    Ozaltin F, Bilginer Y, Gülhan B, Bajin I, Erdogan O, Hayran M, Yılmaz E, Ozen S.
    Clin Rheumatol; 2014 Jul 01; 33(7):969-74. PubMed ID: 24740462
    [Abstract] [Full Text] [Related]

  • 9. A novel cluster of patients with Familial Mediterranean Fever (FMF) in southern Italy.
    Bonfrate L, Scaccianoce G, Palasciano G, Ben-Chetrit E, Portincasa P.
    Eur J Clin Invest; 2017 Sep 01; 47(9):622-629. PubMed ID: 28678379
    [Abstract] [Full Text] [Related]

  • 10. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial.
    Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Johnson A, Park G, Barron KS, Weisman MH, Pashinian N, Reiff AO, Samuels J, Wright DA, Kastner DL, Lovell DJ.
    Ann Intern Med; 2012 Oct 16; 157(8):533-41. PubMed ID: 23070486
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial.
    Koga T, Sato S, Miyamoto J, Hagimori N, Kawazoe Y, Arinaga K, Fukushima C, Yamamoto H, Kawakami A.
    Trials; 2018 Dec 29; 19(1):715. PubMed ID: 30594222
    [Abstract] [Full Text] [Related]

  • 12. Can the Thiol/Disulfide Imbalance Be a Predictor of Colchicine Resistance in Familial Mediterranean Fever?
    Omma A, Sandikci SC, Kücüksahin O, Alisik M, Erel O.
    J Korean Med Sci; 2017 Oct 29; 32(10):1588-1594. PubMed ID: 28875601
    [Abstract] [Full Text] [Related]

  • 13. Interventions for reducing inflammation in familial Mediterranean fever.
    Yin X, Tian F, Wu B, Xu T.
    Cochrane Database Syst Rev; 2022 Mar 29; 3(3):CD010893. PubMed ID: 35349164
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever.
    Gül A, Ozdogan H, Erer B, Ugurlu S, Kasapcopur O, Davis N, Sevgi S.
    Arthritis Res Ther; 2015 Sep 04; 17(1):243. PubMed ID: 26337145
    [Abstract] [Full Text] [Related]

  • 15. Successful management of colchicine resistant familial Mediterranean fever patients with a standardized canakinumab treatment protocol: a case series and literature review.
    Eren Akarcan S, Dogantan S, Edeer Karaca N, Aksu G, Kutukculer N.
    Rheumatol Int; 2020 Jan 04; 40(1):161-168. PubMed ID: 31273456
    [Abstract] [Full Text] [Related]

  • 16. The remarkable characteristics of the children with colchicine-resistant familial Mediterranean fever in Turkey.
    Sahin N, Ozdemir Cicek S, Pac Kisaarslan A, Poyrazoglu MH, Gunduz Z, Dusunsel R.
    Mod Rheumatol; 2022 Jan 05; 32(1):177-185. PubMed ID: 33775204
    [Abstract] [Full Text] [Related]

  • 17. Subclinical inflammation in a case of menstruation-induced familial Mediterranean fever: A case report.
    Hara K, Endo Y, Ishida M, Fujita Y, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Umeda M, Fukui S, Nishino A, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Migita K, Kawakami A, Koga T.
    Medicine (Baltimore); 2018 Sep 05; 97(38):e12305. PubMed ID: 30235678
    [Abstract] [Full Text] [Related]

  • 18. Canakinumab treatment in four children with colchicine resistant familial mediterranean fever.
    Ozkan S, Atas B.
    J Pak Med Assoc; 2017 Jun 05; 67(6):945-947. PubMed ID: 28585601
    [Abstract] [Full Text] [Related]

  • 19. Colchicine, Biologic Agents and More for the Treatment of Familial Mediterranean Fever. The Old, the New, and the Rare.
    Portincasa P.
    Curr Med Chem; 2016 Jun 05; 23(1):60-86. PubMed ID: 26572612
    [Abstract] [Full Text] [Related]

  • 20. An open-label continuation trial of tocilizumab for familial Mediterranean fever with colchicine ineffective or intolerance: Study protocol for investigator-initiated, multicenter, open-label trial.
    Koga T, Hagimori N, Sato S, Morimoto S, Hosogaya N, Fukushima C, Yamamoto H, Kawakami A.
    Medicine (Baltimore); 2020 Jan 05; 99(1):e18328. PubMed ID: 31895769
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.